Profile: MYOS RENS Technology Inc (MYOS.OQ)
22 Jul 2019
MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, incorporated on April 11, 2007, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focusing on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. The Company is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin.
The Company has completed a human clinical trial of Fortetropin for suppressing free serum myostatin levels. The Company's research program is evaluating various active proteins, lipids and peptides in Fortetropin. The Company is also building a small molecule and biologics discovery program focused on regulators of myostatin synthesis and activation and the different pathways that act upon muscle development.
The Company has entered into a research and development agreement with Cloud Pharmaceuticals, Inc., (Cloud), to discover product candidates related to the inhibition of targets in the myostatin regulatory pathway, as well as inflammatory mediators associated with sarcopenia and cachexia. The research is focused on the development of product candidates related to the myostatin pathway. The Company focuses on evaluating the physiological activity of these peptides on myostatin.
The Company competes with Eli Lilly and Co., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Scholar Rock, Acceleron Pharma Inc, PepsiCo Inc., Glanbia Plc, GNC Holdings, The Coca-Cola Company, GlaxoSmithKline, Abbott Laboratories, Nestle S.A. and Universal Nutrition.
MYOS RENS Technology Inc
45 Horsehill Rd Ste 106
CEDAR KNOLLS NJ 07927-2009